<code id='68DC3CEC75'></code><style id='68DC3CEC75'></style>
    • <acronym id='68DC3CEC75'></acronym>
      <center id='68DC3CEC75'><center id='68DC3CEC75'><tfoot id='68DC3CEC75'></tfoot></center><abbr id='68DC3CEC75'><dir id='68DC3CEC75'><tfoot id='68DC3CEC75'></tfoot><noframes id='68DC3CEC75'>

    • <optgroup id='68DC3CEC75'><strike id='68DC3CEC75'><sup id='68DC3CEC75'></sup></strike><code id='68DC3CEC75'></code></optgroup>
        1. <b id='68DC3CEC75'><label id='68DC3CEC75'><select id='68DC3CEC75'><dt id='68DC3CEC75'><span id='68DC3CEC75'></span></dt></select></label></b><u id='68DC3CEC75'></u>
          <i id='68DC3CEC75'><strike id='68DC3CEC75'><tt id='68DC3CEC75'><pre id='68DC3CEC75'></pre></tt></strike></i>

          fashion

          fashion

          author:leisure time    Page View:79
          Sammy Kimball for STAT

          Can biotech startups survive a downturn? Is Covid-19 a good business? And when did ophthalmology get so dramatic?

          We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, we discuss what some recent layoffs and a reverse merger mean for biotech in 2023. We’ll also discuss the latest news in the life sciences, including a dramatic saga in ocular medicine, the volatile business of Covid-19, and some major milestones in gene therapy.

          advertisement

          For more on what we cover, here’s the news on Celsius Therapeutics; here’s more on EQRx; here’s the latest on Apellis Pharmaceuticals; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

          Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

          And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

          explore

          Medicare details structure of new drug price negotiation program
          Medicare details structure of new drug price negotiation program

          MedicareonFridayreleasednewdetailsabouthowitsnewdrugpricenegotiationprogramwillwork,justtwomonthsbef

          read more
          Eli Lilly’s chief scientist on obesity drugs, gene editing, and more
          Eli Lilly’s chief scientist on obesity drugs, gene editing, and more

          DanSkovronsky,EliLilly'schiefscientificofficer,atthe2023STATSummit.STATPHILADELPHIA—Inasense,theannu

          read more
          FDA approval of Sarepta Duchenne genetic therapy gives me hope
          FDA approval of Sarepta Duchenne genetic therapy gives me hope

          Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

          read more

          Researchers use wearables data and AI to predict preterm birth risk

          AdobeForalltheirpotentialtodrivechangesinhealth,wearableshavestruggledtogainafootholdinmedicine.Thed